#RegenerativeMedicine

Thai patients and their families living with Parkinson’s disease received hopeful news this week after the US Food and Drug Administration (FDA) approved a first-of-its-kind stem cell therapy, XS-411, for Phase 1 clinical trials in the United States. Developed by biotech firm Xellsmart, this innovative therapy harnesses induced pluripotent stem cells (iPSCs) to regenerate the healthy, dopamine-producing neurons lost in patients with Parkinson’s. This marks a milestone in neurodegenerative disease treatment and offers a look toward the future of regenerative medicine, not only in the US but potentially in Thailand as global clinical research expands (Parkinson’s News Today).